Equity Profile

INDV

Indivior Pharmaceuticals, Inc.

Health CarePharmaceuticals$4.5B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Indivior Pharmaceuticals Beats on EPS, Stock Up 7.7%

Metric	Actual	Expected	Surprise
EPS	$0.96	$0.66	+50.71%
Revenue	N/A	$273M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Indivior Pharmaceuticals Beats on EPS, Stock Up 7.7%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.96	$0.66	+50.71%
Revenue	N/A	$273M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Indivior's strong earnings per share performance significantly exceeded expectations, leading to a 7.7% increase in stock price. However, revenue figures were not disclosed, leaving some uncertainty about overall financial health. Investors may view the EPS beat as a positive sign for the company's profitability moving forward.

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for addiction and related disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.66

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$273M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for addiction and related disorders. With a market cap of $4 billion, it plays a crucial role in addressing public health issues, particularly in the area of opioid dependence.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+68.40%

Avg Stock Reaction

+9.86%

Last Quarter Recap

In Q4-2025, Indivior reported an EPS of $0.82, significantly beating the estimate of $0.65. The stock reacted positively, increasing by 0.24% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Indivior to continue its strong performance with an EPS of $0.66 and revenue of $273 million. The company has a history of beating earnings expectations.

Bull Case

If Indivior maintains its trend of exceeding EPS estimates, it could see a strong stock price increase, especially given the positive market sentiment.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.

Key Metrics to Watch

EPS

$0.66

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$273M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.66?

A continued trend of beating EPS estimates could reinforce investor confidence and drive the stock price higher.

What are the revenue expectations for the upcoming quarter?

Revenue performance will indicate market demand for Indivior's products and could significantly influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for Indivior to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

Indivior has consistently beaten EPS estimates in the last three quarters, suggesting strong operational performance.

The options market is pricing in a larger move than historical averages, indicating expectations of volatility that may not be justified.

The company's focus on addiction treatments aligns with increasing public health priorities, potentially driving higher demand.

Key Risk

If EPS comes in below $0.61, it would challenge the current bullish sentiment and raise concerns about the company's growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce the company's strong growth narrative or raise red flags about its future prospects.

Bull Confirmed If

An EPS of $0.70 or higher would confirm the bullish outlook and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.61 would validate the bearish case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±19.85%

Historical Avg

±9.9%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±19.8% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

41.9%

Calls (5K)P/C Ratio: 1.52Puts (44K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Indivior beats expectations, history suggests the stock could rise by an average of 10.58%, confirming its strong growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss could lead to a significant decline, with historical data suggesting an average drop of around 10.58%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Insights into market demand for addiction treatments.
3Management's outlook on future revenue growth.
4Comments on cost management and operational efficiency.
5Any changes in regulatory environment affecting the business.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

VZReported

Verizon Communications Inc.

Congress activity

RecapView

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for addiction and related disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.66

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$273M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+68.40%

Avg Stock Reaction

+9.86%

Last Quarter Recap

In Q4-2025, Indivior reported an EPS of $0.82, significantly beating the estimate of $0.65. The stock reacted positively, increasing by 0.24% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Indivior to continue its strong performance with an EPS of $0.66 and revenue of $273 million. The company has a history of beating earnings expectations.

Bull Case

If Indivior maintains its trend of exceeding EPS estimates, it could see a strong stock price increase, especially given the positive market sentiment.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.

Key Metrics to Watch

EPS

$0.66

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$273M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.66?

A continued trend of beating EPS estimates could reinforce investor confidence and drive the stock price higher.

What are the revenue expectations for the upcoming quarter?

Revenue performance will indicate market demand for Indivior's products and could significantly influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for Indivior to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

Indivior has consistently beaten EPS estimates in the last three quarters, suggesting strong operational performance.

The options market is pricing in a larger move than historical averages, indicating expectations of volatility that may not be justified.

The company's focus on addiction treatments aligns with increasing public health priorities, potentially driving higher demand.

Key Risk

If EPS comes in below $0.61, it would challenge the current bullish sentiment and raise concerns about the company's growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce the company's strong growth narrative or raise red flags about its future prospects.

Bull Confirmed If

An EPS of $0.70 or higher would confirm the bullish outlook and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.61 would validate the bearish case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±19.85%

Historical Avg

±9.9%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±19.8% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

41.9%

Calls (5K)P/C Ratio: 1.52Puts (44K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Indivior beats expectations, history suggests the stock could rise by an average of 10.58%, confirming its strong growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss could lead to a significant decline, with historical data suggesting an average drop of around 10.58%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Insights into market demand for addiction treatments.
3Management's outlook on future revenue growth.
4Comments on cost management and operational efficiency.
5Any changes in regulatory environment affecting the business.